Journal
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Volume 1874, Issue 2, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.bbcan.2020.188434
Keywords
Tumor; Immunotherapy; Tumor-associated macrophages (TAMs)
Categories
Funding
- National Science and Technology Major Projects of New Drugs [2018ZX09201018-013]
- National Science and Technology Major Project for Infectious Disease Control [2017ZX10203206-004]
- National Natural Science Foundation of China [81101728]
Ask authors/readers for more resources
Macrophages are important effector cells of the innate immune system and are also major components of the tumor microenvironment (TME). Macrophages that are abundant in the TME are called tumor-associated macrophages (TAMs). As TAMs promote strong tumor angiogenesis and support tumor cell survival, they are closely related to tumor growth. Several studies have demonstrated that reducing the density or effects of TAMs can inhibit the growth of tumors, making them targets for cancer immunotherapy, which has become a research hot spot. Several clinical and preclinical trials have studied drugs that inhibit the effects of and reduce the population of phagocytes that target TAMs achieve cancer immunotherapy. In this paper, we summarize the various methods of targeting TAMs for tumor immunotherapy, focusing on TAM mechanisms, sources, and polarization.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available